# Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

> **NCT07252479** · PHASE1 · RECRUITING · sponsor: **Adlai Nortye Biopharma Co., Ltd.** · enrollment: 91 (estimated)

## Conditions studied

- Solid Tumors (Phase 1)
- RAS Mutation

## Interventions

- **DRUG:** AN9025 oral capsule

## Key facts

- **NCT ID:** NCT07252479
- **Lead sponsor:** Adlai Nortye Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-28
- **Primary completion:** 2028-01-31
- **Final completion:** 2028-06-01
- **Target enrollment:** 91 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07252479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07252479, "Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07252479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*